Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.66 |
| ▸ | IKZF3 | Q9UKT9 | 14/20 | 0.66 |
| ▸ | TNF | P01375 | 6/20 | 0.65 |
| ▸ | IL1B | P01584 | 4/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24816732 | 0.91 | CRBN (0.65) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24816820 | 0.89 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24745418 | 0.89 | CRBN (0.63) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30121832 | 0.89 | CRBN (0.63) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24745411 | 0.88 | CRBN (0.60) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30121914 | 0.88 | CRBN (0.60) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL20645750 | 0.87 | CRBN (0.70) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL21303951 | 0.87 | CRBN (0.70) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL3542188 | 0.87 | CRBN (0.70) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL22360689 | 0.86 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-03-09 | — | — | US | disclosed |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-03 | — | — | US | disclosed |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| US-20210283261-A1 | Compositions and Methods for Treating ALK-Mediated Cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-09-16 | — | — | US | disclosed |
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-06-01 | — | — | US | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200071291-A1 | A CLASS OF ISOINDOLONE-IMIDE RING-1,3-DIONE-2-ENE COMPOUNDS, COMPOSITION AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-03-05 | — | — | US | disclosed |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-11-07 | — | — | US | disclosed |
| US-20190016703-A1 | BIFUNCTIONAL COMPOUNDS FOR HER3 DEGRADATION AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885IKZF3 1741/4885TNF 4031/4885 |
| US-20190016703-A1 | BIFUNCTIONAL COMPOUNDS FOR HER3 DEGRADATION AND METHODS OF USE | MDM2, ERBB2, ITCH | CRBN 134/4885IKZF3 301/4885TNF 4559/4885 |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | CRBN 421/4885IKZF3 1032/4885TNF 3223/4885 |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | CRBN 527/4885IKZF3 3509/4885TNF 3971/4885 |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | PTK6, NEK6, GRK6 | CRBN 871/4885IKZF3 3529/4885TNF 3417/4885 |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | CRBN 527/4885IKZF3 3509/4885TNF 3971/4885 |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | CDK4, CDK6, CDK2 | CRBN 185/4885IKZF3 1998/4885TNF 4349/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | CRBN 3528/4885IKZF3 2946/4885TNF 1474/4885 |
| US-20200071291-A1 | A CLASS OF ISOINDOLONE-IMIDE RING-1,3-DIONE-2-ENE COMPOUNDS, COMPOSITION AND USE THEREOF | ATG7, MLST8, BECN1 | CRBN 846/4885IKZF3 889/4885TNF 4082/4885 |
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | ATG7, MLST8, BECN1 | CRBN 978/4885IKZF3 701/4885TNF 4202/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | CRBN 194/4885IKZF3 1172/4885TNF 4422/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885IKZF3 1741/4885TNF 4031/4885 |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | CDK4, CDK6, CDK2 | CRBN 185/4885IKZF3 1998/4885TNF 4349/4885 |
| US-20210283261-A1 | Compositions and Methods for Treating ALK-Mediated Cancer | ALK, BCR, TP53 | CRBN 54/4885IKZF3 440/4885TNF 3879/4885 |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | MKNK1, MKNK2, MTOR | CRBN 527/4885IKZF3 3509/4885TNF 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.